Unknown

Dataset Information

0

Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?


ABSTRACT: PI3K and CDK4/6 inhibitors (CDK4/6i) are targeted therapies approved to treat advanced breast cancer; CDK4/6is are more widely used. Here, we discuss trials that examine PI3K inhibitors with novel drug combinations, including a CDK4/6i, given data implicating the pathway in CDK 4/6 resistance.See related articles by Lu et al., p. 408, and Tolaney et al., p. 418.

SUBMITTER: Clark AS 

PROVIDER: S-EPMC8278622 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10247331 | biostudies-literature
| S-EPMC9752919 | biostudies-literature
| EGAS00001000991 | EGA
| S-EPMC10459070 | biostudies-literature
| S-EPMC6236629 | biostudies-literature
| S-EPMC10499925 | biostudies-literature
| S-EPMC7385619 | biostudies-literature
| S-EPMC9448295 | biostudies-literature
2018-05-16 | PXD006561 | Pride
2018-05-31 | GSE99675 | GEO